HPN-100 + Placebo

Phase 2Completed

0 watching 0 views this week⚡ Active

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Cirrhosis

Conditions

Cirrhosis, Hepatic Encephalopathy

Trial Timeline

Dec 1, 2009 → Apr 1, 2012

NCT ID

NCT00999167

About HPN-100 + Placebo

HPN-100 + Placebo is a phase 2 stage product being developed by Amgen for Cirrhosis. The current trial status is completed. This product is registered under clinical trial identifier NCT00999167. Target conditions include Cirrhosis, Hepatic Encephalopathy.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT00999167	Phase 2	Completed	Dec 1, 2009	Apr 1, 2012	Cirrhosis

Competing Products

20 competing products in Cirrhosis

See all competitors

Product	Company	Stage	Hype Score
SYNB1020	Synlogic	Phase 1/2	33
peginterferon alfa-2a 180μg + peginterferon alfa-2a 90μg + ribavirin	Chugai Pharmaceutical	Phase 3	77
Fenofibrate IDD-P (Insoluble Drug Delivery-Micro Particle)	Shionogi	Phase 2	52
Mesenchymal Stem Cell	Rohto Pharmaceutical	Pre-clinical	23
Bumetanide + Furosemide	Johnson & Johnson	Phase 3	77
Mesenchymal stem cell	Rohto Pharmaceutical	Phase 1/2	41
Zibotentan	AstraZeneca	Phase 1	33
Part A: Placebo (matching zibotentan capsule & matching dapagliflozin tablet) + Part A: zibotentan (dose B) + dapagliflozin + Part B: Placebo (matching zibotentan capsule & matching dapagliflozin tablet) + Part B: placebo (matching zibotentan capsule) + dapagliflozin + Part B: zibotentan (dose A) + dapagliflozin + Part B: zibotentan (dose B) + dapagliflozin + Part B: zibotentan (dose C) + dapagliflozin	AstraZeneca	Phase 2	52
Placebo (placebo matching zibotentan capsule and placebo matching dapagliflozin tablet) + Zibotentan + placebo (placebo matching dapagliflozin tablet) + Zibotentan + dapagliflozin	AstraZeneca	Phase 2	52
ARQ 197	Merck	Phase 1	33
Grazaoprevir/Elbasavir + Grazaoprevir/Elbasavir/RBV	Merck	Approved	85
Steroids + Basiliximab + Tacrolimus + Enteric-coated Mycophenolic acid (EC-MPA)	Novartis	Approved	85
Telbivudine + Enecavir + Adefovir	Novartis	Approved	85
Serelaxin + Placebo	Novartis	Phase 2	52
Terlipressin acetate + Serelaxin (RLX030)	Novartis	Phase 2	52
Pasireotide	Novartis	Phase 1	33
Placebo Comparator + Experimental: Seladelpar 50 mg + Experimental: Seladelpar / MBX-8025 200 mg	Gilead Sciences	Phase 2	51
TDF/FTC/LPV/r + Placebo	Gilead Sciences	Pre-clinical	22
MBX-8025 2 mg Capsule + MBX-8025 5 mg Capsule + MBX-8025 10 mg Capsule	Gilead Sciences	Phase 2	51
Seladelpar 5 mg Capsule + Seladelpar 10 mg Capsule	Gilead Sciences	Phase 3	76

Other Products from Amgen